Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (D
about
Surgical management of localised renal cell carcinomaSurgical management of localised renal cell carcinomaImmunotherapy for metastatic renal cell carcinoma.Adjuvant therapy for locally advanced renal cell cancer: a systematic review with meta-analysisThe role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma.Adjuvant therapy for renal cell carcinoma: past, present, and futureTargeted therapies for non-clear renal cell carcinoma.Renal cell carcinoma and the use of sorafenib.Systemic adjuvant therapies in renal cell carcinomaNeoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?Adjuvant treatment for renal cell carcinoma.Management of locally advanced renal cell carcinoma.Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial.New drug therapies for advanced renal cell carcinoma.Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy.Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines.Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.Adjuvant therapy in renal cell carcinoma-past, present, and future.Immunotherapy for renal cell cancer in the era of targeted therapy.Adjuvant and neoadjuvant therapy in renal cell carcinoma.Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents.Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?Renal cell carcinoma in children and adolescents.Systemic therapy for advanced renal cell carcinoma.Neoadjuvant and adjuvant treatment of renal cell carcinoma.Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma.Adjuvant therapy for high-risk localized kidney cancer- emerging evidence and future clinical trials.Node-positive renal cell carcinoma in the absence of distant metastases: predictors of cancer-specific mortality in a population-based cohort.Renal cell cancer: what can we learn from pre-operative studies?Partial nephrectomy and enbloc liver resection using a bipolar radiofrequency device for renal cell carcinoma invading the liver.Randomized controlled study of natural interferon α as adjuvant treatment for stage II or III renal cell carcinoma.Unclassified renal cell carcinoma: an analysis of 85 cases.Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?Dual energy CT allows for improved characterization of response to antiangiogenic treatment in patients with metastatic renal cell cancer.Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma.NierenzellkarzinomIs there a role for adjuvant therapy after surgery in “high risk for recurrence” kidney cancer? An update on current concepts
P2860
Q24186058-878410A8-4A9C-4E0E-AA81-69E6EF65DD38Q24236818-4789FDFF-EDFF-4452-991F-86178BDE6E46Q30234458-EE346D08-9ECB-4B9A-B232-797166E215B2Q33858807-44E6FCF0-2483-401D-B239-730CE8F47DEDQ33946316-C3CA644F-09CF-4492-8127-4065A1ED439EQ34005127-2DADE346-2038-4214-A4D7-77185C003CFDQ34412479-1762A1AB-B501-46BE-B719-8E078435ED04Q35166782-FB118D89-DB1C-44B0-B156-26F7A1EB87C1Q35569322-C49E7E8B-D41D-47B0-862C-E9758D839B83Q35916894-210A62B1-0311-4768-AC4E-5A1A455A10D0Q36291489-4AE3DC3B-CC4F-49BC-8C1E-E7F870719FB4Q36429718-7A124459-D7FF-4A88-8F02-ABE27267936AQ36555667-C1E063E7-7C8B-4A6C-A3A6-7B2B11C2DDA8Q36611853-55F7CA59-5D9C-407C-BC7E-88A18E7B0668Q36691810-D220C0FA-21CC-4B9D-8692-B25071B7A13AQ36995364-08E02010-2D7E-45FF-B43E-A9D34ACDDD55Q37000740-37BA7D6E-F6C5-4692-8E89-8B996068A6E0Q37071204-8FC83FCD-45DC-4E80-81EA-16D5F322840BQ37153437-700BF743-5B7B-4A7D-A262-423494E8F634Q37183451-270E5700-CFB4-40D1-9BCC-9AF41B25EEB6Q37492442-058CDF24-99D2-43F1-9FB9-760F5D3236EFQ37508012-AEB0CBB4-8770-4C1C-8224-8F97D4925014Q37765583-8C1DF113-9C30-438A-B607-2F035DEF46DEQ37812610-2BA21EBF-B533-47A7-AF4E-261A80318352Q37905583-19907190-8938-470F-9507-CD2A162BE5A0Q38020243-8E353061-BC44-4680-B8BE-0BAF6823C1ABQ38188423-C8AAEEE9-BA1A-494D-A083-BADEEE6983EFQ38686841-E4893501-6EA4-4853-A2CF-0F0B94A5568EQ39691300-D6CB8544-6165-442C-A719-3DECD2AC78E5Q42175050-6B12D69D-94FA-4222-8D9F-87CA7E55923DQ42583941-A03707D2-3C74-4007-B0F8-94BF95231E57Q44587950-76285B88-C812-47C2-AA19-54AA11DD69EBQ44728580-004352E4-3FBA-43BD-8CA9-A2992F3026DAQ47269814-6296ED00-F2BD-4FF3-A8DA-DC7D6CA44B91Q47397616-D0D41FBB-A71B-4D45-ACDC-DD4D08A8A044Q51454930-B705BC75-3BFB-4F89-9913-0A5CD37BA75FQ54436763-0F4F1A46-054B-467D-A1B8-41852168D290Q56639125-8329EFC6-64EA-4FD6-87C9-07C676C28AA0Q59126184-170CBF99-9F35-442F-A7CE-EC99CA953EF8
P2860
Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (D
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Adjuvant treatment with interl ...... ma Chemoimmunotherapy Group (D
@ast
Adjuvant treatment with interl ...... ma Chemoimmunotherapy Group (D
@en
Adjuvant treatment with interl ...... inoma Chemoimmunotherapy Group
@nl
type
label
Adjuvant treatment with interl ...... ma Chemoimmunotherapy Group (D
@ast
Adjuvant treatment with interl ...... ma Chemoimmunotherapy Group (D
@en
Adjuvant treatment with interl ...... inoma Chemoimmunotherapy Group
@nl
prefLabel
Adjuvant treatment with interl ...... ma Chemoimmunotherapy Group (D
@ast
Adjuvant treatment with interl ...... ma Chemoimmunotherapy Group (D
@en
Adjuvant treatment with interl ...... inoma Chemoimmunotherapy Group
@nl
P2093
P2860
P356
P1476
Adjuvant treatment with interl ...... ma Chemoimmunotherapy Group (D
@en
P2093
German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group (DGCIN)
H H Wöltjen
H Heynemann
J Atzpodien
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602443
P407
P577
2005-03-01T00:00:00Z
P5875
P6179
1042545705